Each year, The Conference Forum holds the R&D Leadership Summit, a private event for primarily senior level R&D executives from mid to large pharma and biotech companies to address timely and relevant issues impacting R&D decision-making. The theme for 2018 is “Growth: Where will it come from?” The agenda is made up of approximately 20 topic sessions, with a speaking faculty of 50 presenters who are mostly from senior R&D leadership, with CEOs, investors, analysts, representatives from the payer community and government.
The annual opening keynote will be given by Fred Hassan, Managing Director, Healthcare, Warburg Pincus. Keynote discussions scheduled so far include Dr Mikael Dolsten, Global R&D Head, Pfizer; Brent Saunders, CEO, Allergan; Chris Viehbacher, Managing Partner, Gurnet Point Capital; Steve Frank, Chairman, Global Health Care Group, JP Morgan; and Sir Andrew Witty, Former CEO, GSK.
We are delighted to welcome our veteran and new leadership to the speaking faculty, including co-chairs Dr Bahija Jallal, EVP, Medimmune and David Nicholson, PhD, Chief R&D Officer, Allergen; as well as veteran and new leadership to the speaking faculty, including Dr Moncef Slaoui, former Chairman of Vaccines, GSK and Partner, Medicxi; Dr Elias Zerhouni, President, Global R&D, Sanofi; Dr Menelas Pangalos, EVP Innovative Medicines and Early Development, AstraZeneca; Dr Roy Baynes, SVP, Head Global Clinical Development, CMO, Merck; Dr Alise Reicin, Head of Global Clinical Development, EMD Serono; Dr Monika Lessl, Head of Corporate Innovation and R&D, Bayer AG; Dr Julie Gerberding, EVP and Chief Patient Officer, Merck; Marc Boutin, CEO, National Health Council; Dr Ron Cohen, President and CEO, Acorda Therapeutics; Vivek Ramaswamy, CEO, Roivant Sciences;and Ronny Gal, Senior Analyst, Healthcare, Sandford Bernstein.
We are especially pleased to welcome the following new speakers participating for the first time at the Summit:
Mark Bodmer, PhD, President of R&D, CSO, Evelo
Katrine Bosley, CEO, Editas Medicine
David Maris, MBA, Equity Research Analyst, Managing Director, Wells Fargo
Bill Meury, Chief Commercial Officer, Allergan
Joerg Moeller, MD, Corporate EVP, Head of Global Development, Bayer AG
Sylke Poehling, PhD, SVP and Global Head, Strategy, Portfolio & Clinical Operations, Pharma Research & Early Development, Roche
Dan Wechsler, CEO, Melinta Therapeutics
Chris Viehbacher, Managing Partner, Gurnet Point Capital
Sue Windham-Bannister, PhD, Former CEO, MLS
Investor Panelists Announced:
Alexis Borisy, Partner, Third Rock Ventures
Francesco De Rubertis, PhD, Partner, Medicxi
Genghis Lloyd-Harris, MD, PhD, MBA, Partner, Abingworth
Mark Simon, MBA, Partner, Torreya Partners
Elizabeth Stoner, MD, Managing Director, MPM Capital
Many thanks to the executive team at PRA Health Sciences for their support, to Dr Thomas Koestler, Executive Director Health Care, Vatera Health Care Partners, for his guidance, and to the entire speaking faculty, who bring their vast experience together to identify and collaborate over ideas that will advance therapeutics for the benefit of patients.
The format of the Summit is a combination of presentations, interviews and panel discussions. The event provides plenty of networking opportunities, including breakfast, luncheons, a welcome reception, the annual dinner and networking breaks.
The Summit is open exclusively to senior level R&D executives from clinical stage pharmaceutical, biotech, medical device and vaccine companies.
Our audience is as much a part of the event as our speaking faculty. Our ultimate goal is to foster a Summit environment that inspires positive change to advance R&D and to provide support for the leaders behind the movement.
For questions about the R&D Leadership Summit, please contact Valerie@tcfllc.org or Jennifer Moran at Jennifer@tcfllc.org.
Executive Director, Business Development
*Please note the leadership R&D program for emerging biotechs is held in Boston each May and is called the CMO Summit.
"One of the best conferences and a great group of leaders and organizers and all done with such thought put into the agenda and topics."
- Mark Currie, Ironwood Pharma